Cancer and liver cirrhosis: implications on prognosis and management
暂无分享,去创建一个
M. Trauner | Michael Trauner | Wolfgang Sieghart | Markus Peck-Radosavljevic | M. Pinter | W. Sieghart | Matthias Pinter | M. Peck‐Radosavljevic
[1] Pei-Jer Chen,et al. Influences of tobacco and alcohol use on hepatocellular carcinoma survival , 2012, International journal of cancer.
[2] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[3] N. Dobbs,et al. Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. , 2003, European journal of cancer.
[4] R. Goldberg,et al. Phase 1 and Pharmacokinetic Study of Intravenous Irinotecan in Refractory Solid Tumor Patients with Hepatic Dysfunction , 2006, Clinical Cancer Research.
[5] G. Carrafiello,et al. Radiofrequency Ablation of Intrahepatic Cholangiocarcinoma: Preliminary Experience , 2010, CardioVascular and Interventional Radiology.
[6] T. Pawlik,et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. , 2014, JAMA surgery.
[7] Y. Kodera,et al. Retrospective Study on the Impact of Hepatitis B and Hepatitis C Virus Infection on Hematopoietic Stem Cell Transplantation in Japan , 2002, International journal of hematology.
[8] J. Bruix,et al. Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects , 2010, Seminars in liver disease.
[9] F. Hucke,et al. Transarterial chemoembolization: modalities, indication, and patient selection. , 2015, Journal of hepatology.
[10] R. Adams,et al. Model for End-Stage Liver Disease (MELD) Predicts Nontransplant Surgical Mortality in Patients With Cirrhosis , 2005, Annals of surgery.
[11] J. Bosch,et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[12] P. Tekkis,et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing , 2007, British Journal of Cancer.
[13] S. Belknap,et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] William M. Lee,et al. Cancer chemotherapy I: hepatocellular injury. , 2007, Clinics in liver disease.
[15] A. Alberti,et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation , 2003, Bone Marrow Transplantation.
[16] H. Hasegawa,et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients , 1985, Cancer.
[17] J. Bruix,et al. A meta‐analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma , 2010, Hepatology.
[18] J. Tolstrup,et al. Smoking and risk of liver cirrhosis: a population-based cohort study , 2013, Scandinavian journal of gastroenterology.
[19] P. Ferenci,et al. Hepatocellular carcinoma in Central Europe: prognostic features and survival , 2001, Gut.
[20] I. Song,et al. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions , 2015, BMC Cancer.
[21] B. Sangro,et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Ferlay,et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.
[23] H. Ashamalla,et al. Radiation Oncology in the Treatment of Hepatocellular Carcinoma , 2015 .
[24] J. Vauthey,et al. Perioperative chemotherapy for resectable hepatic metastases , 2008, The Lancet.
[25] T. Sauerbruch,et al. Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis , 2009, British journal of pharmacology.
[26] ndrea,et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.
[27] R. Wiesner,et al. The new liver allocation system: Moving toward evidence‐based transplantation policy , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[28] K. Wakasa,et al. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus–related hepatocellular carcinoma , 2000, Cancer.
[29] W. Koizumi,et al. Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study , 2012, Journal of Gastroenterology.
[30] W. Lau,et al. A Comparative Study of Antiviral Therapy After Resection of Hepatocellular Carcinoma in the Immune-Active Phase of Hepatitis B Virus Infection , 2009, Annals of Surgical Oncology.
[31] H. Heinzl,et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. , 2014, Journal of hepatology.
[32] H. Li,et al. The Role of Liver Transplantation for Intrahepatic Cholangiocarcinoma: A Single-Center Experience , 2011, European Surgical Research.
[33] Wei F. Chen,et al. The Roles of Albumin Levels in Head and Neck Cancer Patients with Liver Cirrhosis Undergoing Tumor Ablation and Microsurgical Free Tissue Transfer , 2012, PloS one.
[34] S. Takai,et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy , 2005, European journal of haematology.
[35] J. Bruix,et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma , 2004, Hepatology.
[36] J. Cho,et al. Clinical Outcomes of Patients with Liver Cirrhosis Who Underwent Curative Surgery for Gastric Cancer: A Retrospective Multi-center Study , 2008, Digestive Diseases and Sciences.
[37] J. Bruix,et al. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.
[38] T M Therneau,et al. A model to predict survival in patients with end‐stage liver disease , 2001, Hepatology.
[39] M. Choi,et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. , 2013, Journal of hepatology.
[40] S. Beckebaum,et al. Liver transplantation as a primary indication for intrahepatic cholangiocarcinoma: a single-center experience. , 2008, Transplantation proceedings.
[41] G. Benea,et al. Chemoembolization (TACE) of Unresectable Intrahepatic Cholangiocarcinoma with Slow-Release Doxorubicin-Eluting Beads: Preliminary Results , 2008, CardioVascular and Interventional Radiology.
[42] V. Mazzaferro,et al. Resection and Liver Transplantation for Hepatocellular Carcinoma , 2005, Seminars in liver disease.
[43] Y. Rotman,et al. Emerging trends in hepatocellular carcinoma incidence and mortality , 2015, Hepatology.
[44] E. Björnsson,et al. Increased risk for malignant neoplasms among patients with cirrhosis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[45] M. Quante,et al. Impact of the MELD allocation after its implementation in liver transplantation , 2011, Scandinavian journal of gastroenterology.
[46] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[47] J. Bosch,et al. Measurement of portal pressure and its role in the management of chronic liver disease. , 2006, Seminars in liver disease.
[48] B. Chauffert,et al. Management of colon cancer in patients with cirrhosis: A review. , 2015, Surgical oncology.
[49] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[50] O. Jeong,et al. Analysis of 30-Day Postdischarge Morbidity and Readmission after Radical Gastrectomy for Gastric Carcinoma: A Single-Center Study of 2107 Patients With Prospective Data , 2015, Medicine.
[51] M. Dumont,et al. European Association for the Study of the Liver , 1971 .
[52] M. Ducreux,et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] M. Manns,et al. [Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. , 2011, Zeitschrift fur Gastroenterologie.
[54] S. Taylor-Robinson,et al. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. , 2008, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[55] M. Miyazaki,et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan , 2010, British Journal of Cancer.
[56] J. Bruix,et al. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta‐analysis , 2015, Hepatology.
[57] S. Jegatheeswaran,et al. Management of colorectal cancer presenting with synchronous liver metastases , 2014, Nature Reviews Clinical Oncology.
[58] J B Saunders,et al. Epidemiology of alcoholic liver disease. , 1993, Bailliere's clinical gastroenterology.
[59] T. Pawlik,et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. , 2014, Journal of hepatology.
[60] T. Nakajima. Gastric cancer treatment guidelines in Japan , 2002, Gastric Cancer.
[61] H. El‐Serag,et al. Risk factors for cholangiocarcinoma , 2011, Hepatology.
[62] S. Truant,et al. The short‐ and long‐term outcomes of pancreaticoduodenectomy for cancer in child a patients are acceptable: A patient‐control study from the Surgical French Association report for pancreatic surgery , 2015, Journal of surgical oncology.
[63] N. Terrault,et al. The option of HBIG-free prophylaxis against recurrent HBV. , 2012, Journal of hepatology.
[64] D. Nelson,et al. Management of viral hepatitis in hematologic malignancies. , 2008, Blood reviews.
[65] M. Mejías,et al. Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats. , 2012, American journal of physiology. Gastrointestinal and liver physiology.
[66] T. Reiberger,et al. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma – a pilot study , 2012, Alimentary pharmacology & therapeutics.
[67] J. Lammer,et al. Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. , 2015, Radiology.
[68] M. Colombo,et al. Field‐practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy , 2011, Hepatology.
[69] H. Torres,et al. Challenges in managing hepatitis C virus infection in cancer patients. , 2014, World journal of gastroenterology.
[70] Vivek Roy,et al. N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer , 2008 .
[71] R. Shanks,et al. Can severe vincristine neurotoxicity be prevented? , 2004, Cancer Chemotherapy and Pharmacology.
[72] R. Wolfe,et al. The Survival Benefit of Liver Transplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[73] P. Galle,et al. Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis , 2009, Journal of clinical gastroenterology.
[74] D. Valla,et al. Assessment of Prognosis of Cirrhosis , 2008, Seminars in liver disease.
[75] D. Shouval,et al. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies , 2007, British journal of haematology.
[76] Nandita Mitra,et al. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. , 2008, International journal of radiation oncology, biology, physics.
[77] M. S. Longhi,et al. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. , 2002, The Lancet. Oncology.
[78] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[79] A. Davies,et al. Commentary: Oncologic drugs in patients with organ dysfunction: a summary. , 2007, The oncologist.
[80] H. Blum,et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy , 2012, European journal of gastroenterology & hepatology.
[81] D. McDonald,et al. Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.
[82] R. de Franchis. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. , 2015, Journal of hepatology.
[83] P. Kamath,et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts , 2000, Hepatology.
[84] Jean-Michel Pawlotsky,et al. EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.
[85] T. Therneau,et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. , 2008, The New England journal of medicine.
[86] Pingfu Fu,et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] D. Heo,et al. High titers of anti‐HBs prevent rituximab‐related viral reactivation in resolved hepatitis B patient with non‐Hodgkin's lymphoma , 2016, Journal of medical virology.
[88] J. Ward,et al. Reactivation of Hepatitis B During Immunosuppressive Therapy: Potentially Fatal Yet Preventable , 2012, Annals of Internal Medicine.
[89] Jae Young Lee,et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. , 2014, Radiology.
[90] Yoshiyuki Suzuki,et al. HBcrAg is a predictor of post‐treatment recurrence of hepatocellular carcinoma during antiviral therapy , 2010, Liver international : official journal of the International Association for the Study of the Liver.
[91] Amrik Singh,et al. Surgery in the patient with liver disease. , 2009, Anesthesiology clinics.
[92] J. Pillot,et al. REACTIVATION OF HEPATITIS B , 1989, The Lancet.
[93] O. Sauer,et al. Definition of stereotactic body radiotherapy , 2013, Strahlentherapie und Onkologie.
[94] R. Wiesner,et al. Model for end-stage liver disease (MELD) and allocation of donor livers. , 2003, Gastroenterology.
[95] T. Therneau,et al. Risk factors for mortality after surgery in patients with cirrhosis. , 2007, Gastroenterology.
[96] R. Pugh,et al. Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.
[97] C. G. Child,et al. Surgery and portal hypertension. , 1964, Major problems in clinical surgery.
[98] C. Compton,et al. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.
[99] L. Påhlman,et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. , 2015, Cancer treatment reviews.
[100] R. Wolfe,et al. Trends in Organ Donation and Transplantation in the United States, 1996–2005 , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[101] J. Bosch,et al. The management of portal hypertension: rational basis, available treatments and future options. , 2008, Journal of hepatology.
[102] S. Todo,et al. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma , 2009, Journal of Gastroenterology.
[103] S. Monfardini,et al. Pharmacokinetics of vinorelbine in patients with liver metastases , 1996, Clinical pharmacology and therapeutics.
[104] A. Jemal,et al. Global Cancer Statistics , 2011 .
[105] G. Cabibbo,et al. Should cirrhosis change our attitude towards treating non‐hepatic cancer? , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[106] M. Aapro,et al. Gemcitabine--a safety review. , 1998, Anti-cancer drugs.
[107] Franco Ameglio,et al. Cisplatin-induced hepatic toxicity. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] F. Farinati,et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function , 2011, Cancer Chemotherapy and Pharmacology.
[109] P. Hall,et al. Toxicities of Gemcitabine in Patients with Severe Hepatic Dysfunction , 2010, The Annals of pharmacotherapy.
[110] Riccardo Lencioni,et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.
[111] A. Hettinger,et al. Time course of total cysteine, glutathione and homocysteine in plasma of patients with chronic hepatitis C treated with interferon-alpha with and without supplementation with N-acetylcysteine. , 1998, Journal of Hepatology.
[112] A. Lok,et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. , 1991 .
[113] P. Schirmacher,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.
[114] E. Bugianesi. Review article: steatosis, the metabolic syndrome and cancer , 2005, Alimentary pharmacology & therapeutics.
[115] M. Kudo,et al. Validation of a New Prognostic Staging System for Hepatocellular Carcinoma: A Comparison of the Biomarker-Combined Japan Integrated Staging Score, the Conventional Japan Integrated Staging Score and the BALAD Score , 2008, Oncology.
[116] K. Owzar,et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[117] R. Wolfe,et al. Longitudinal assessment of mortality risk among candidates for liver transplantation , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[118] G. Rosner,et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[119] T. López-Cuadrado,et al. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma , 2009, BMC gastroenterology.
[120] F. Nevens,et al. Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin , 2015, Transplantation.
[121] M. Vovk,et al. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. , 1999, Hepato-gastroenterology.
[122] M. Perry,et al. Hepatotoxicity of chemotherapy. , 2001, Expert opinion on drug safety.
[123] V. Lo Re,et al. Evaluating Hepatitis B Virus Reactivation During Solid Tumor Chemotherapy: Evidence to Guide Pretreatment Hepatitis B Screening and Prophylaxis , 2016, Annals of Internal Medicine.
[124] Jae Young Lee,et al. Radiofrequency Ablation for Intrahepatic Recurrent Hepatocellular Carcinoma: Long-Term Results and Prognostic Factors in 168 Patients with Cirrhosis , 2013, CardioVascular and Interventional Radiology.
[125] D. Cunningham,et al. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[126] E. Zuckerman,et al. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies , 1998, Cancer.
[127] C. G. Child,et al. The liver and portal hypertension , 1964 .
[128] F. Nevens,et al. Portal hypertension: from pathophysiology to clinical practice , 2005, Liver international : official journal of the International Association for the Study of the Liver.
[129] J. Joo,et al. Worse outcome of sorafenib therapy associated with ascites and Child‐Pugh score in advanced hepatocellular carcinoma , 2013, Journal of gastroenterology and hepatology.
[130] W. Rilling,et al. Transarterial Therapies for the Treatment of Intrahepatic Cholangiocarcinoma , 2013, Seminars in Interventional Radiology.
[131] S. Zeuzem,et al. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study. , 2013, Clinical therapeutics.
[132] R. Franchis,et al. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. , 2005, Journal of hepatology.
[133] R. Groszmann,et al. The hepatic venous pressure gradient: Anything worth doing should be done right , 2004, Hepatology.
[134] S. Ramalingam,et al. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function , 2012, Cancer Chemotherapy and Pharmacology.
[135] J. Bruix,et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. , 1996, Gastroenterology.
[136] F. González‐Huix,et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis , 2004, Gut.
[137] H. Bismuth,et al. Two-Stage Hepatectomy: A Planned Strategy to Treat Irresectable Liver Tumors , 2000, Annals of surgery.
[138] M. Makuuchi,et al. The surgical approach to HCC: Our progress and results in Japan , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[139] D. Kershenobich,et al. Hepatic Fibrosis , 1955, Gastroenterology.
[140] H. Lenz,et al. Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study , 2013, Clinical Cancer Research.
[141] Riccardo Lencioni,et al. Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.
[142] Kurinchi Gurusamy,et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. , 2010, Journal of hepatology.
[143] G. Poggi,et al. OEM-TACE: A New Therapeutic Approach in Unresectable Intrahepatic Cholangiocarcinoma , 2009, CardioVascular and Interventional Radiology.
[144] O. Mir,et al. Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib , 2011, PloS one.
[145] S. Ahn,et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection , 2007, Liver international : official journal of the International Association for the Study of the Liver.
[146] K. Raja,et al. Portal vein thrombosis in cirrhosis. , 2014, Journal of clinical and experimental hepatology.
[147] R. Benjamin,et al. Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high‐dosage schedule , 1974, Cancer.
[148] J. Pawlotsky,et al. EASL Recommendations on Treatment of Hepatitis C 2016. , 2017, Journal of hepatology.
[149] D. Fraker,et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol , 2011, Cancer.
[150] P. Kim,et al. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. , 2011, AJR. American journal of roentgenology.
[151] Y. Falck‐Ytter,et al. American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Reactivation During Immunosuppressive Drug Therapy , 2014 .
[152] V. Mazzaferro,et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. , 2011, Cancer treatment reviews.
[153] Wolfgang Vogel,et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. , 2009, The oncologist.
[154] B. Xing,et al. Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma. , 2012, Journal of vascular and interventional radiology : JVIR.
[155] J. Doroshow,et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[156] E. Schiff,et al. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[157] G. Widmann,et al. Stereotactic Radiofrequency Ablation of Unresectable Intrahepatic Cholangiocarcinomas: A Retrospective Study , 2012, CardioVascular and Interventional Radiology.
[158] H. Thomas,et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998 , 2001, Gut.
[159] M. Makuuchi,et al. A new staging system for mass‐forming intrahepatic cholangiocarcinoma , 2001, Cancer.
[160] R. Labianca,et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[161] Fan Fs,et al. Withdrawal of immunosuppressive therapy in allogeneic bone marrow transplantation reactivates chronic viral hepatitis C. , 1991 .
[162] J. Bosch,et al. Complications of cirrhosis. I. Portal hypertension. , 2000, Journal of hepatology.
[163] S. Friedman,et al. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis , 2010, Hepatology.
[164] Steven E Schild,et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.
[165] F. Greene. AJCC cancer staging handbook , 2002 .
[166] J. Bruix,et al. Novel advancements in the management of hepatocellular carcinoma in 2008. , 2008, Journal of hepatology.
[167] Kai-Ping Chang,et al. The impacts of liver cirrhosis on head and neck cancer patients undergoing microsurgical free tissue transfer: an evaluation of flap outcome and flap-related complications. , 2009, Oral oncology.
[168] J. Verweij,et al. Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements , 2008, Clinical pharmacology and therapeutics.
[169] W. Palmer,et al. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. , 2012, Journal of hepatology.
[170] N. Finlayson,et al. Clinical evaluation of liver disease. , 1995, Bailliere's clinical gastroenterology.
[171] A. Burroughs,et al. EASL Clinical Practice Guidelines: Liver transplantation. , 2016, Journal of hepatology.
[172] F. Hucke,et al. Clinical characteristics of patients with hepatocellular carcinoma in Austria – is there a need for a structured screening program? , 2011, Wiener klinische Wochenschrift.
[173] R. Wolfe,et al. Trends in Organ Donation and Transplantation in the United States, 1999–2008 , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[174] R. de Franchis. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. , 2000, Journal of hepatology.
[175] P. Kim,et al. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. , 2015, Journal of vascular and interventional radiology : JVIR.
[176] Xiang‐Dong Wang,et al. Alcohol and cancer: genetic and nutritional aspects , 2004, Proceedings of the Nutrition Society.
[177] J. Bruix,et al. Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation , 1999, Hepatology.
[178] J. Bruix,et al. “Very Early” Intrahepatic Cholangiocarcinoma in Cirrhotic Patients: Should Liver Transplantation Be Reconsidered in These Patients? , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[179] Ashraf Mansour Habib Mansour,et al. Abdominal operations in patients with cirrhosis: still a major surgical challenge. , 1997, Surgery.
[180] J. Hoofnagle,et al. Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy , 2008, Annals of Internal Medicine.
[181] J. Vauthey,et al. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. , 2009, The Lancet. Oncology.
[182] K. McGlynn,et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? , 2004, Journal of hepatology.
[183] S. Yamasaki. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. , 2003, Journal of hepato-biliary-pancreatic surgery.
[184] H. Sørensen,et al. Liver disease and 30-day mortality after colorectal cancer surgery: a Danish population-based cohort study , 2013, BMC Gastroenterology.
[185] S. Marubashi,et al. The long‐term outcomes after curative resection for mass‐forming intrahepatic cholangiocarcinoma associated with hepatitis C viral infection: A multicenter analysis by Osaka Hepatic Surgery Study Group , 2014, Journal of surgical oncology.
[186] D. Larson,et al. Colorectal adenocarcinoma in cirrhotic patients. , 2003, Journal of the American College of Surgeons.
[187] G. D’Amico,et al. Competing risks and prognostic stages of cirrhosis: a 25‐year inception cohort study of 494 patients , 2014, Alimentary pharmacology & therapeutics.
[188] C. Boni,et al. Refining sorafenib therapy: lessons from clinical practice. , 2015, Future oncology.
[189] V. Arroyo,et al. Compensated cirrhosis: Natural history and prognostic factors , 1987, Hepatology.
[190] Rumiko Okamoto,et al. [Hepatotoxicity of chemotherapy]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.
[191] Gang Liu,et al. Prognostic Value of Cirrhosis for Intrahepatic Cholangiocarcinoma After Surgical Treatment , 2011, Journal of Gastrointestinal Surgery.
[192] K. Kondo,et al. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. , 2013, Journal of vascular and interventional radiology : JVIR.
[193] R. Arellano,et al. Locoregional Therapy for Cholangiocarcinoma , 2017, Digestive Disease Interventions.
[194] B. Carr,et al. Causes of Death in Patients with Unresectable Hepatocellular Carcinoma , 2007, Digestive Diseases and Sciences.
[195] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.
[196] P. Kim,et al. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. , 2011, European journal of radiology.
[197] J. Olsen,et al. Risk of liver and other types of cancer in patients with cirrhosis: A nationwide cohort study in Denmark , 1998, Hepatology.
[198] D. Sinn,et al. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. , 2015, Journal of hepatology.
[199] J. Figueras,et al. Spanish Experience in Liver Transplantation for Hilar and Peripheral Cholangiocarcinoma , 2004, Annals of surgery.
[200] S. Zeuzem,et al. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2011, Journal of hepatology.
[201] V. Mazzaferro,et al. Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions , 2012, Seminars in Liver Disease.
[202] K. Hong,et al. Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma. , 2010, Seminars in oncology.
[203] D. Carbone. Smoking and cancer. , 1992, The American journal of medicine.
[204] F. Izzo,et al. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients , 1998, Hepatology.
[205] R. Gill,et al. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: A systematic review and pooled analysis , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[206] R. Chung,et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[207] A. Burroughs,et al. Current management of hepatitis B virus infection before and after liver transplantation , 2009, Liver international : official journal of the International Association for the Study of the Liver.
[208] Johnny C. Hong,et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. , 2011, Archives of surgery.
[209] V. Goh,et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[210] R. Amathieu,et al. Assessment of risk for non-hepatic surgery in cirrhotic patients. , 2012, Journal of hepatology.
[211] J. Pawlotsky,et al. EASL Recommendations on Treatment of Hepatitis C 2015. , 2015, Journal of hepatology.
[212] I-S Lee,et al. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. , 2011, Clinical radiology.
[213] T. de Baère,et al. Percutaneous transhepatic portal vein embolization: rationale, technique, and outcomes. , 2008, Seminars in interventional radiology.
[214] S. Schenker,et al. Antecedent liver disease and drug toxicity. , 1999, Journal of hepatology.
[215] P. Aiello,et al. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb , 2005, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[216] Masato Hareyama,et al. The combination of olaparib and camptothecin for effective radiosensitization , 2012, Radiation oncology.
[217] H. Wedemeyer,et al. The New Era of Interferon-Free Treatment of Chronic Hepatitis C , 2015, Visceral Medicine.
[218] W. Guo,et al. Consideration of the Role of Radiotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Analysis of 75 Patients , 2006, Cancer journal.
[219] H. Rhim,et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies , 2009, Hepatology.
[220] G. Lau,et al. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy — pathogenesis and management , 2001, Reviews in medical virology.
[221] D. Cunningham,et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.
[222] A. Singal,et al. Meta‐analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma , 2010, Alimentary pharmacology & therapeutics.
[223] D. Palmer,et al. The ART strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. , 2014, Journal of hepatology.
[224] M. Dobritz,et al. Pharmacokinetic and Clinical Phase II Trial of Imatinib in Patients with Impaired Liver Function and Advanced Hepatocellular Carcinoma , 2005, Oncology.
[225] H. Heinzl,et al. The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma , 2013, Hepatology.
[226] R. Bruno,et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[227] R. Labianca,et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[228] R. Stauber,et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib , 2011, Alimentary pharmacology & therapeutics.
[229] Zhao-You Tang,et al. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients , 2010, BMC Cancer.
[230] Angelo Andriulli,et al. Radiofrequency Thermal Ablation vs. Percutaneous Ethanol Injection for Small Hepatocellular Carcinoma in Cirrhosis: Meta-Analysis of Randomized Controlled Trials , 2009, The American Journal of Gastroenterology.
[231] M. Makuuchi,et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. , 2008, Gastroenterology.
[232] V. Paradis,et al. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib , 2010, European journal of gastroenterology & hepatology.
[233] H. Polk,et al. Clarification of Risk Factors for Abdominal Operations in Patients with Hepatic Cirrhosis , 1984, Annals of surgery.
[234] M. Mejías,et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats , 2009, Hepatology.
[235] A. Letai,et al. Cancer, coagulation, and anticoagulation. , 1999, The oncologist.
[236] Han‐Chieh Lin,et al. Anti‐VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH‐cirrhotic rat , 2014, Liver international : official journal of the International Association for the Study of the Liver.
[237] B. Luo,et al. Hepatic and biliary damage after transarterial chemoembolization for malignant hepatic tumors: incidence, diagnosis, treatment, outcome and mechanism. , 2011, Critical reviews in oncology/hematology.
[238] S. Fan,et al. Extended Hepatic Resection for Hepatocellular Carcinoma in Patients with Cirrhosis: Is It Justified? , 2002, Annals of surgery.
[239] T. Therneau,et al. Evidence-based incorporation of serum sodium concentration into MELD. , 2006, Gastroenterology.
[240] S. Chevret,et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. , 1999, Journal of hepatology.
[241] F. Pruvot,et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma , 2011, Cancer.
[242] S. Kubo,et al. Adjuvant Therapy after Curative Resection for Hepatocellular Carcinoma Associated with Hepatitis Virus , 2013, Liver Cancer.
[243] S. Fan,et al. The use of single‐agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child‐Pugh B liver cirrhosis , 2012, Cancer.
[244] M. Blachier,et al. Report Title: The burden of liver disease in Europe: a review of available epidemiological data , 2013 .
[245] A. Absalom,et al. Green light for liver function monitoring using indocyanine green? An overview of current clinical applications , 2014, Anaesthesia.
[246] A. Burroughs,et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[247] C. Liao,et al. Predicting postoperative morbidity and mortality by model for endstage liver disease score for patients with head and neck cancer and liver cirrhosis , 2011, Head & neck.
[248] J. Rumessen,et al. Systematic review with meta‐analyses of studies on the association between cirrhosis and liver metastases , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.
[249] P. Metrakos,et al. Liver transplantation for incidental cholangiocarcinoma: Analysis of the Canadian experience , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[250] Guang-shun Yang,et al. Prognosis after resection for hepatitis B virus-associated intrahepatic cholangiocarcinoma. , 2015, World journal of gastroenterology.
[251] S. Truant,et al. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child‐Pugh score , 2011, Alimentary pharmacology & therapeutics.
[252] G. Rosner,et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[253] D. de Freitas,et al. [Alcohol and cancer]. , 1997, Acta medica portuguesa.
[254] C. Hsiung,et al. A revisit of prophylactic lamivudine for chemotherapy‐associated hepatitis B reactivation in non‐Hodgkin's lymphoma: A randomized trial , 2008, Hepatology.
[255] H. Lemke,et al. An Information Technology Framework for Predictive, Preventive and Personalised Medicine , 2015 .
[256] P. Bachellier,et al. Sinusoidal Injury Increases Morbidity After Major Hepatectomy in Patients With Colorectal Liver Metastases Receiving Preoperative Chemotherapy , 2008, Annals of surgery.
[257] M. Slevin,et al. Predicting etoposide toxicity: relationship to organ function and protein binding. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[258] A. Walker,et al. Causes of Death in People with Liver Cirrhosis in England Compared with the General Population: A Population-Based Cohort Study , 2015, The American Journal of Gastroenterology.
[259] Jürgen Rehm,et al. Liver Cirrhosis Mortality in Europe, with Special Attention to Central and Eastern Europe , 2010, European Addiction Research.
[260] R. Busuttil,et al. Liver transplantation for cholangiocellular carcinoma: Analysis of a single‐center experience and review of the literature , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[261] T. Vogl,et al. Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study , 2009, CardioVascular and Interventional Radiology.
[262] G. Lau. Hepatitis B reactivation after chemotherapy: two decades of clinical research , 2008, Hepatology international.
[263] M. Highley,et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study , 2009, British Journal of Cancer.
[264] P. Bhosale,et al. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[265] G. Rosner,et al. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[266] M. Russell. Complications following hepatectomy. , 2015, Surgical oncology clinics of North America.
[267] R. Williams,et al. Tolerance after liver transplantation: does it exist and can immunosuppression be withdrawn? , 1999, Journal of hepatology.
[268] Charles M. Miller,et al. Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors , 2012, Acta oncologica.
[269] M. Michael,et al. Part II: Liver function in oncology: towards safer chemotherapy use. , 2008, The Lancet. Oncology.
[270] M. Kudo,et al. Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan , 2015, Cancer.
[271] T. Asselah,et al. Allogeneic hematopoietic cell transplant in HCV-infected patients. , 2008, Journal of hepatology.
[272] Bill Bynum,et al. Lancet , 2015, The Lancet.
[273] L. Mariani,et al. Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence‐based analysis of 15 years of experience , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[274] M. Mitterhauser,et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. , 2009, Journal of hepatology.
[275] G. D’Amico,et al. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.
[276] D. Amadori,et al. Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. , 2011, Gastrointestinal cancer research : GCR.
[277] M. Michael,et al. Part I: Liver function in oncology: biochemistry and beyond. , 2008, The Lancet. Oncology.
[278] K. Leung,et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system , 2002, Cancer.
[279] T. Greten,et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. , 2010, European journal of gastroenterology & hepatology.
[280] G. D’Amico,et al. Survival and prognostic indicators in compensated and decompensated cirrhosis , 1986, Digestive Diseases and Sciences.
[281] F. Zoulim,et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT , 2011, Bone Marrow Transplantation.
[282] Hitoshi Sato,et al. Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice , 2009, Cancer science.
[283] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .